2011
DOI: 10.1016/j.ejphar.2010.10.109
|View full text |Cite
|
Sign up to set email alerts
|

Design of novel melanocortin receptor ligands: Multiple receptors, complex pharmacology, the challenge

Abstract: The major pharmacophore for the melanocortin 1,3,4 and 5 receptors is the sequence -His-Phe-Arg-Trp-. There is a need for potent, biologically stable, receptor selective ligands, both agonists and antagonists, for these receptors. In this report we briefly examine the structural and biophysical approaches we have taken to develop selective agonist and antagonist ligands that can cross (or not) the blood brain barrier. Remaining questions and unmet needs are also discussed.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
35
0

Year Published

2013
2013
2020
2020

Publication Types

Select...
5
1
1

Relationship

2
5

Authors

Journals

citations
Cited by 18 publications
(35 citation statements)
references
References 32 publications
0
35
0
Order By: Relevance
“…Melanotan I (MTI) [Nle 4 ,D-Phe 7 ]α-MSH is a potent analog of α-MSH with activity at the MC1, MC3, MC4, and MC5 receptors and good in vivo stability and biodistribution, but poor blood-brain barrier permeability (Hruby et al, 2011). Melanotan II (MTII), Ac-Nle-c[Asp 5 ,DPhe 7 ,Lys 10 ]α-MSH-NH2, is of similar potency and promiscuity as MTI but enhanced in vivo stability (T 1/2 : 1-2 h) and blood-brain barrier permeability because of its cyclic structure (Cai et al, 2005).…”
Section: Melanocortin Receptor Agonistsmentioning
confidence: 99%
“…Melanotan I (MTI) [Nle 4 ,D-Phe 7 ]α-MSH is a potent analog of α-MSH with activity at the MC1, MC3, MC4, and MC5 receptors and good in vivo stability and biodistribution, but poor blood-brain barrier permeability (Hruby et al, 2011). Melanotan II (MTII), Ac-Nle-c[Asp 5 ,DPhe 7 ,Lys 10 ]α-MSH-NH2, is of similar potency and promiscuity as MTI but enhanced in vivo stability (T 1/2 : 1-2 h) and blood-brain barrier permeability because of its cyclic structure (Cai et al, 2005).…”
Section: Melanocortin Receptor Agonistsmentioning
confidence: 99%
“…The need for new radiopharmaceuticals able to diagnose tumor in the early stages is evident. Native a-MSH has an extremely short biological half-life because it is easily hydrolyzed by proteases and also the methionine residue in a-MSH can be oxidized [12]. Newer generation agents have been designed to enhance their potency toward MC1 receptor, including peptides with linear structures [13][14][15][16] and cyclic structures [17][18][19].…”
Section: Introductionmentioning
confidence: 99%
“…79-84 However, the response of obese volunteers to compounds targeting MC4Rs in the clinic has thus far been discouraging due to limited effectiveness and side effects on cardiovascular function. 85 MC4Rs are not, however, the only member of the melanocortin receptor family involved in metabolic homeostasis.…”
Section: The “Leptin-melanocortin” Pathway: a Canonical Pathway LImentioning
confidence: 99%